Nancy Cox PhD director of the Vanderbilt Genetics Institute is the recipient of the 2023 ASHG Leadership Award from the American Society of Human Genetics.

Vanderbilt researchers are bolstering the fight against cancer with technology that enhances the effectiveness of T cells that attack tumors.

Fluorescent nanoparticles clearly identified colonic adenomas precursors to colorectal cancer in mice and the formulation should translate to clinical use in humans.

An international coalition of biomedical researchers co-led by Vanderbilts Alexander Bick MD PhD has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients risk of blood cancer.

Early detection of lymphedema, which occurs in 20% of patients following breast cancer treatment, may improve therapeutic options for patients.

VICC is one of three institutions launching the first phase of a collaboration to advance precision oncology through the creation of a clinico-genomic dataset with an international reach.

VUMC is leading an initiative to establish a streamlined process for collection of family health histories that could set the stage for a standardized system to make the information easily accessible.

A newly identified protein interaction that affects cell cycle regulation may be an attractive target for cancer therapy.

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

James Dewar and colleagues have identified a role for the enzyme topoisomerase II in reducing replication errors during the final stage of DNA synthesis.